Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature.

Abstract

OBJECTIVE:

Corticosteroids are the treatment of choice in most forms of vasculitis. However, their role in the primary treatment of Kawasaki disease (KD) is controversial. Our aim was to conduct a meta-analysis to assess the clinical course and coronary artery outcome of adding corticosteroids to standard therapy [intravenous immunoglobulin (IVIG) + aspirin] in patients with acute KD.

METHODS:

We included randomised trials comparing the addition of corticosteroids to conventional primary therapy for Kawasaki disease.

RESULTS:

A total of four studies were identified, which included 447 patients. The meta-analysis revealed a significant reduction in re-treatments with IVIG in patients receiving corticosteroid plus standard therapy compared with standard therapy alone [odds ratio (OR) 0.48; 95% confidence interval (CI): 0.24- 0.95]. There was however no significant reduction in the incidence of coronary artery aneurysms among patients who received corticosteroid therapy plus standard therapy, compared with standard therapy alone for either up to a month (OR 0.74; 95% CI: 0.23-2.40) or over one month ([OR 0.74; 95% CI: 0.37-1.51). Similarly no significant differences between treatment groups were noted in incidence of adverse events (OR 0.81; 95% CI: 0.05-0.88).

CONCLUSION:

The inclusion of corticosteroids in regimens for the initial treatment of Kawasaki disease decreased rates of re-treatment with intravenous immunoglobulin. However the addition of corticosteroids to standard therapy did not decrease the incidence of coronary aneurysms or adverse events.

• Authors: Ganesh Athappan, Seth Gale, Thirumalaikolundusubramanian Ponniah
• Journal: Cardiovascular journal of Africa (Cardiovasc J Afr) 2009 Jul-Aug Vol. 20 Issue 4 Pg. 233-6 ISSN: 1995-1892 [Print] South Africa
• PMID: 19701534 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)

Chemical References

• Glucocorticoids
• Immunoglobulins, Intravenous
• Aspirin

Topics

• Aspirin (therapeutic use)
• Combined Modality Therapy
• Coronary Aneurysm (etiology, prevention & control)
• Glucocorticoids (therapeutic use)
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Mucocutaneous Lymph Node Syndrome (complications, drug therapy)